Pericarditis resident survival guide: Difference between revisions
Gerald Chi (talk | contribs) m (→Management) |
No edit summary |
||
Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Acute pericarditis refers to inflammation of the pericardial sac, which can be dry, fibrinous or effusive, independent from its aetiology. The term [[myopericarditis]], or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation resulting in global or regional myocardial dysfunction, elevations of [[troponin|troponins]], MB creatine | [[Acute pericarditis]] refers to inflammation of the pericardial sac, which can be dry, fibrinous or effusive, independent from its aetiology. The term [[myopericarditis]], or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation resulting in global or regional myocardial dysfunction, elevations of [[troponin|troponins]], [[creatine kinase|MB creatine kinase]], [[myoglobin]] and [[tumour necrosis factor]]. | ||
==Causes== | ==Causes== | ||
Line 15: | Line 15: | ||
* Autoimmune: [[Rheumatoid arthritis]], [[Sjögren’s syndrome]], [[SLE]], [[systemic sclerosis]], [[systemic vasculitis]] | * Autoimmune: [[Rheumatoid arthritis]], [[Sjögren’s syndrome]], [[SLE]], [[systemic sclerosis]], [[systemic vasculitis]] | ||
* Bacterial: [[Coxiella burnetii]], [[pneumococcus]], [[staphylococcus]], [[streptococcus]], [[tuberculosis]] | * Bacterial: [[Coxiella burnetii]], [[pneumococcus]], [[staphylococcus]], [[streptococcus]], [[tuberculosis]] | ||
* Cardiovascular: [[Dressler's syndrome]] | * Cardiovascular: [[Dressler's syndrome]], [[postpericardiotomy syndrome]], posttraumatic pericarditis | ||
*[[Idiopathic]] | |||
* Metabolic: [[Myxedema]], [[uremia]] | |||
* Neoplastic: [[Breast cancer]], [[leukemia]], [[lung cancer]], [[lymphoma]] | * Neoplastic: [[Breast cancer]], [[leukemia]], [[lung cancer]], [[lymphoma]] | ||
* Viral: [[Adeno virus]], [[CMV]], [[coxsackie]], [[EBV]], [[echovirus]], [[HBV | * Viral: [[Adeno virus]], [[CMV]], [[coxsackie]], [[EBV]], [[echovirus]], [[HBV]], [[HIV]], [[herpes|human herpes virus 6]], [[influenza]], [[mumps]], [[parvovirus B19]], [[rubella]], [[varicella]] | ||
==Management== | ==Management== | ||
The following is an algorithm depicting the management of [[acute pericarditis]] in adults.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056 }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693 }} </ref><ref name="pmid20177006">{{cite journal| author=Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y| title=Controversial issues in the management of pericardial diseases. | journal=Circulation | year= 2010 | volume= 121 | issue= 7 | pages= 916-28 | pmid=20177006 | doi=10.1161/CIRCULATIONAHA.108.844753 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20177006 }} </ref> | The following is an algorithm depicting the management of [[acute pericarditis]] in adults.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056 }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693 }} </ref><ref name="pmid20177006">{{cite journal| author=Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y| title=Controversial issues in the management of pericardial diseases. | journal=Circulation | year= 2010 | volume= 121 | issue= 7 | pages= 916-28 | pmid=20177006 | doi=10.1161/CIRCULATIONAHA.108.844753 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20177006 }} </ref> | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the | {{familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the clinical, EKG and imaging findings'''<br> | ||
❑ Characteristic [[chest pain]] <br> | ❑ Characteristic [[chest pain]] <br> | ||
Line 31: | Line 32: | ||
:❑ Heard during [[atrial systole]], [[ventricular systole]] and rapid ventricular filling during early [[diastole]] | :❑ Heard during [[atrial systole]], [[ventricular systole]] and rapid ventricular filling during early [[diastole]] | ||
❑ Suggestive EKG changes <br> | ❑ Suggestive EKG changes <br> | ||
:❑ Diffuse ST elevation with reciprocal ST depression in leads aVR and V1 | :❑ Diffuse [[ST elevation]] with reciprocal ST depression in leads aVR and V1 | ||
❑ Suggestive [[echocardiography]] changes <br> | ❑ Suggestive [[echocardiography]] changes <br> | ||
:❑ New or worsening [[pericardial effusion]] <br> | :❑ New or worsening [[pericardial effusion]] <br> | ||
Line 55: | Line 56: | ||
:❑ [[Orthopnea]] <br> | :❑ [[Orthopnea]] <br> | ||
:❑ [[Dizziness]] <BR> | :❑ [[Dizziness]] <BR> | ||
:❑ [[Hoarsenes]] ([[recurrent laryngeal nerve]] compression) <br> | |||
:❑ [[Hiccups]] ([[phrenic nerve]] compression) <BR> | |||
:❑ [[Abdominal pain]] ([[mesenteric ischemia]]) <BR> | |||
:❑ [[Nausea]] ([[diaphragm]] irritation) <BR> | |||
:❑ [[Loss of consciousness]]<br> | :❑ [[Loss of consciousness]]<br> | ||
:❑ [[Cool extremities]]<br> | :❑ [[Cool extremities]]<br> | ||
Line 85: | Line 90: | ||
:❑ [[Anticoagulants]] | :❑ [[Anticoagulants]] | ||
:❑ [[Cyclosporine]] | :❑ [[Cyclosporine]] | ||
:❑ [[ | :❑ [[Cyclophosphamide]] | ||
:❑ [[Cytarabine]] | :❑ [[Cytarabine]] | ||
:❑ [[Daunorubicin]] | :❑ [[Daunorubicin]] | ||
Line 94: | Line 99: | ||
:❑ [[Sulfa drugs]] | :❑ [[Sulfa drugs]] | ||
:❑ [[Thiazides]] | :❑ [[Thiazides]] | ||
:❑ | :❑ Thrombolytic agents | ||
</div></div><br> | </div></div><br> | ||
❑ Systemic illness | ❑ Systemic illness | ||
Line 113: | Line 118: | ||
❑ Vitals | ❑ Vitals | ||
:❑ [[Pulse]] | :❑ [[Pulse]] | ||
::❑ [[Tachycardia]] ( | ::❑ [[Tachycardia]] (typical) | ||
::❑ [[Bradycardia]] (in [[hypothyroidism]] and [[uremia]]) | ::❑ [[Bradycardia]] (in [[hypothyroidism]] and [[uremia]]) | ||
::❑ [[Pulsus paradoxus]] (in [[cardiac tamponade]]) | ::❑ [[Pulsus paradoxus]] (in [[cardiac tamponade]]) | ||
:❑ [[Blood pressure]] | :❑ [[Blood pressure]] | ||
::❑ Normal ( | ::❑ Normal (typical) | ||
::❑ [[Hypotension]] (in [[cardiac tamponade]]) | ::❑ [[Hypotension]] (in [[cardiac tamponade]]) | ||
:❑ [[Temperature]] | :❑ [[Temperature]] | ||
Line 126: | Line 131: | ||
❑ Cardiovascular: <br> | ❑ Cardiovascular: <br> | ||
:❑ Heart sounds | :❑ Heart sounds | ||
::❑ Normal ( | ::❑ Normal (typical) | ||
::❑ New [[S3]] heart sound | |||
::❑ Distant and muffled (in [[cardiac tamponade]]) | ::❑ Distant and muffled (in [[cardiac tamponade]]) | ||
:❑ [[Pericardial friction rub]] | :❑ [[Pericardial friction rub]] | ||
Line 132: | Line 138: | ||
::❑ Best heard at the left sternal border | ::❑ Best heard at the left sternal border | ||
::❑ Best heard with the diaphragm of the stethoscope | ::❑ Best heard with the diaphragm of the stethoscope | ||
::❑ | ::❑ Varies in intensity overtime and needs reapeated examinations | ||
<center>{{#ev:youtube|watch?v=EUCp_3_vwtw|300}}</center> | <center>{{#ev:youtube|watch?v=EUCp_3_vwtw|300}}</center> | ||
:❑ [[Jugular venous pulse]] | :❑ [[Jugular venous pulse]] | ||
Line 155: | Line 161: | ||
❑ [[troponin|Serum cardiac troponin I and T]] <br> | ❑ [[troponin|Serum cardiac troponin I and T]] <br> | ||
❑ [[Creatine kinase]]: CK-MB <br> | ❑ [[Creatine kinase]]: CK-MB <br> | ||
❑ [[Serum urea]] and [[creatinine]] <br> | ❑ [[myoglobin|Serum myoglobin]] <br> | ||
❑ [[tumour necrosis factor|Serum tumour necrosis factor]] <br> | |||
❑ [[urea|Serum urea]] and [[creatinine]] <br> | |||
---- | ---- | ||
'''Order [[electrocardiogram]] (urgent):'''<br> | '''Order [[electrocardiogram]] (urgent):'''<br> | ||
Line 170: | Line 178: | ||
---- | ---- | ||
❑ [[Chest X-ray]] <br> | ❑ [[Chest X-ray]] <br> | ||
:❑ Clear lung fields | :❑ Clear lung fields | ||
:❑ A flask-shaped, enlarged cardiac silhouette (in [[pericardial effusion]] and [[cardiac tamponade]]) | |||
:❑ Lateral view may reveal | |||
::❑ Thickened pericardial line (in [[pericarditis]], [[pericardial effusion]]) | |||
::❑ Irregular contours of cardiac silhouette (in [[pericarditis|chronic pericarditis]], [[pericardial fibrosis]], post surgery, [[metastasis]]) | |||
[[Image:Pericardial effusion_3.jpg|thumb|150px|left|Pericardial effusion]] | [[Image:Pericardial effusion_3.jpg|thumb|150px|left|Pericardial effusion]] | ||
<br clear="left"/> | <br clear="left"/> | ||
❑ [[Echocardiography]] <br> | ❑ [[Echocardiography]] <br> | ||
:❑ [[Pericarditis echocardiography|Diagnostic]] | :❑ [[Pericarditis echocardiography|Diagnostic]] | ||
:❑ Presence of moderate and large [[pericardial effusion]] | ::❑ Presence of moderate and large [[pericardial effusion]] | ||
:❑ Right atrial collapse | ::❑ Right atrial collapse | ||
:❑ Diastolic collapse of right ventricle and left atrium (specific for cardiac tamponade) | ::❑ Diastolic collapse of [[right ventricle]] and [[left atrium]] (specific for cardiac tamponade) | ||
:❑ | :❑ Check for concomitant heart disease or paracardial pathology | ||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | |!| | | | | | | | | }} | {{familytree | | | | | | | | | | |!| | | | | | | | | }} | ||
Line 192: | Line 203: | ||
{{familytree | | | | | | | D01 | | | | D02 | | | | | | D01=Yes| D02=No or equivocal}} | {{familytree | | | | | | | D01 | | | | D02 | | | | | | D01=Yes| D02=No or equivocal}} | ||
{{familytree | | | | | | | |!| | | |,|-|^|-|-|.| | | }} | {{familytree | | | | | | | |!| | | |,|-|^|-|-|.| | | }} | ||
{{familytree | | | | | | | E01 | | E02 | | | E03 | | E01= | {{familytree | | | | | | | E01 | | E02 | | | E03 | | E01=<div style="float: left; text-align: left; padding:1em;">'''Acute pericarditis'''<br> | ||
---- | |||
'''Or'''<br> | |||
---- | |||
'''[[Myopericarditis]]'''<br> | |||
---- | |||
❑ Elevated cardiac enzymes <BR> | |||
❑ Global or regional myocardial dysfunction on echo <br> | |||
</div>| E02=Consider cardiac MRI (CMR) | E03=Consider [[Pericarditis differential diagnosis|alternative diagnosis]] and treat accordingly}} | |||
{{familytree | | | | | | | |!| | | |!| | | | | | | | }} | {{familytree | | | | | | | |!| | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | |!| | | F01 | | | | | | | F01= Treat as acute pericarditis or myopericarditis if there is delayed enhancement on CMR}} | {{familytree | | | | | | | |!| | | F01 | | | | | | | F01= Treat as [[acute pericarditis]] or [[myopericarditis]] if there is delayed enhancement on CMR}} | ||
{{familytree | | | | | | | |`|-|v|-|'| | | | | | | | }} | {{familytree | | | | | | | |`|-|v|-|'| | | | | | | | }} | ||
{{familytree | | | | | | | | | G01 | | | | | | | | | G01=<div style="float: left; text-align: left; padding:1em;">'''High risk features'''<br> | {{familytree | | | | | | | | | G01 | | | | | | | | | G01=<div style="float: left; text-align: left; padding:1em;">'''High risk features'''<br> | ||
Line 214: | Line 233: | ||
{{familytree | | | | | | H01 | | | | | | H02 | | | | H01=Inpatient treatment| H02=Outpatient treatment}} | {{familytree | | | | | | H01 | | | | | | H02 | | | | H01=Inpatient treatment| H02=Outpatient treatment}} | ||
{{familytree | | | | |,|-|^|-|.| | | |,|-|^|-|.| | | | | }} | {{familytree | | | | |,|-|^|-|.| | | |,|-|^|-|.| | | | | }} | ||
{{familytree | | | | J01 | | J02 | | J03 | | J04 | | | | J01= Stable| J02= Unstable| J03= No pre-existing [[coronary artery disease]] | J04=Pre-existing [[coronary artery disease]]}} | {{familytree | | | | J01 | | J02 | | J03 | | J04 | | | | J01= '''Stable'''| J02= <div style="float: left; text-align: left; padding:1em;">'''Unstable'''<br> | ||
❑ [[Hypotension]] <BR> | |||
❑ [[Cardiac tamponade]] <br> | |||
:❑ [[Pulsus paradoxus]] <br> | |||
:❑ [[Jugular vein distention]] <br></div>| J03= No pre-existing [[coronary artery disease]] | J04=Pre-existing [[coronary artery disease]]}} | |||
{{familytree | | | | |!| | | |!| | | | | | | |!| | | | |}} | {{familytree | | | | |!| | | |!| | | | | | | |!| | | | |}} | ||
{{familytree | | | | I02 | | I03 | | I04 | | I01 | | | | | I02=❑ [[NSAID's]] or [[aspirin]] | {{familytree | | | | I02 | | I03 | | I04 | | I01 | | | | | I02=<div style="float: left; text-align: left; width: 15em; padding:1em;"> | ||
❑ [[NSAID's]] or [[aspirin]] or [[colchicine]] (usual regimen) <BR> | |||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Clinical testing for underlying etiology]] <br> | |||
:❑ Order tests for specific etiologies according to the clinical presentation | |||
❑ [[Pericarditis 1 resident survival guide#Management#Management of recurrent pericarditis|Management of recurrent pericarditis]] <br> | |||
❑ [[Pericardiocentesis]]: <BR> | |||
::❑ High suspicion of purulent or neoplastic [[pericarditis]] | |||
::❑ Asymptomatic pateints with effusions > 20 mm in [[echocardiography]] in [[diastole]] | |||
::❑ Large or symptomatic effusions despite one week of medical therapy</div>| I03=<div style="float: left; text-align: left; padding:1em;"> | |||
❑ Immediately transfer the patient to ICU <BR> | ❑ Immediately transfer the patient to ICU <BR> | ||
❑ Telemetry monitoring and frequent vital checks <BR> | ❑ Telemetry monitoring and frequent vital checks <BR> | ||
❑ Call cardiology team immediately <br> | ❑ Call cardiology team immediately <br> | ||
❑ [[Cardiac tamponade resident survival guide|Management of cardiac tamponade management]] <br> | ❑ [[Cardiac tamponade resident survival guide|Management of cardiac tamponade management]] <br> | ||
:❑ [[Pericardiocentesis]] is life saving in cardiac tamponade | |||
❑ Make sure patient is oxygenating well <BR> | ❑ Make sure patient is oxygenating well <BR> | ||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Clinical testing for underlying etiology]] <BR> | ❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Clinical testing for underlying etiology]] <BR> | ||
❑ [[NSAID's]] or [[aspirin]] | :❑ Order tests for specific etiologies according to the clinical presentation | ||
❑ [[NSAID's]] or [[aspirin]] or [[colchicine]] (usual regimen) </div>| I01=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''[[Aspirin]]'''<br> | |||
---- | ---- | ||
❑ [[aspirin|High-dose aspirin]]: <br> | ❑ [[aspirin|High-dose aspirin]]: <br> | ||
Line 231: | Line 264: | ||
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | :❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | ||
:❑ [[Omeprazole]] (20 mg/day) <br> | :❑ [[Omeprazole]] (20 mg/day) <br> | ||
❑ Stop anticoagulants if patient develops [[pericardial effusion]] <br> | ❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]] <br> | ||
---- | ---- | ||
'''Steroids'''<br> | '''[[Steroids]]'''<br> | ||
---- | ---- | ||
❑ Avoid steroids to treat an initial episode of pericarditis <br> | ❑ Avoid steroids to treat an initial episode of pericarditis <br> | ||
</div>| I04=<div style="float: left; text-align: left; padding:1em;">'''NSAID's'''<br> | </div>| I04=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''NSAID's'''<br> | ||
---- | ---- | ||
❑ [[Ibuprofen]]: <br> | |||
:❑ Preferred<br> | |||
:❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br> | |||
:❑ Gradual tapering every 2-3 days <br> | |||
:❑ Avoid in [[coronary artery disease]] patients<br> | |||
❑ [[Indomethacin]]: <br> | ❑ [[Indomethacin]]: <br> | ||
:❑ Orally 50 mg TDS x 1-2 weeks<br> | :❑ Orally 50 mg TDS x 1-2 weeks<br> | ||
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br> | :❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br> | ||
:❑ Avoid in [[coronary artery disease]] patients<br>Or<br> | :❑ Avoid in [[coronary artery disease]] patients<br>Or<br> | ||
❑ Add gastroprotective agents <br> | ❑ Add gastroprotective agents <br> | ||
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | :❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | ||
:❑ [[Omeprazole]] (20 mg/day) <br> | :❑ [[Omeprazole]] (20 mg/day) <br> | ||
---- | ---- | ||
'''Colchicine'''<br> | '''[[Colchicine]]'''<br> | ||
---- | ---- | ||
❑ Alone or in combination with NSAIDs <br> | ❑ Alone or in combination with [[NSAIDs]] <br> | ||
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR> | ❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR> | ||
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR> | ❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR> | ||
---- | ---- | ||
'''Steroids'''<br> | '''[[Steroids]]'''<br> | ||
---- | ---- | ||
❑ Avoid steroids to treat an initial episode of pericarditis <br> | ❑ Avoid steroids to treat an initial episode of pericarditis <br> | ||
Line 266: | Line 300: | ||
{{familytree | | | | | | | | | | | | |!| | | |!| | |}} | {{familytree | | | | | | | | | | | | |!| | | |!| | |}} | ||
{{familytree | | | | | | | | | | | | K01 | | K02 | | K01=<div style="float: left; text-align: left; padding:1em;">'''Follow up'''<br> | {{familytree | | | | | | | | | | | | K01 | | K02 | | K01=<div style="float: left; text-align: left; padding:1em;">'''Follow up'''<br> | ||
❑ 7 to 10 days | ❑ Observe for recurrences or constriction<br> | ||
❑ Assess at 7 to 10 days for treatment response <br> | |||
❑ At 1 month check blood tests and CRP <BR> | ❑ At 1 month check blood tests and CRP <BR> | ||
❑ Thereafter only if symptoms recur <br> | ❑ Thereafter only if symptoms recur <br> | ||
</div>| K02= <div style="float: left; text-align: left; padding:1em;">'''Hospital admission'''<br> | </div>| K02=<div style="float: left; text-align: left; padding:1em;">'''Hospital admission'''<br> | ||
❑ Indication that the underlying cause may not be viral or idiopathic in nature. <br> | ❑ Indication that the underlying cause may not be viral or idiopathic in nature. <br> | ||
❑ Inpatient therapy <BR> | ❑ Inpatient therapy <BR> | ||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Etiology specific management]] <br> | ❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Etiology specific management]] <br> | ||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | |}} | |||
{{familytree/end}} | |||
===Management of Recurrent Pericarditis=== | |||
{{Family tree/start}} | |||
{{familytree | | | | | | | | | | A01 | | | | | | | | | | A01=Recurrent pericarditis}} | |||
{{familytree | | | | | | | | |,|-|^|-|.| | | | | | | | |}} | |||
{{familytree | | | | | | | | B01 | | B02 | | | | | | | | B01=<div style="float: left; text-align: left; padding:1em;">'''The intermittent type'''<br> | |||
❑ Symptom free interval without therapy <br> | |||
❑ Widely varying symptom free interval | |||
</div>| B02=<div style="float: left; text-align: left; padding:1em;">'''The incessant type'''<br> | |||
❑ Always relapses on discontinuation of anti-inflammatory<br> | |||
</div>}} | |||
{{familytree | | | | | | | | |`|-|v|-|'| | | }} | |||
{{familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the clinical, EKG and imaging findings'''<br> | |||
❑ Characteristic [[Pericarditis history and symptoms|acute pericarditis symptoms]] <br> | |||
❑ Characteristic [[Pericarditis electrocardiogram|acute pericarditis EKG changes]] <br> | |||
❑ Characteristic [[Pericarditis echocardiography|acute pericarditis echocardiography changes]] <br> | |||
❑ Massive [[pericardial effusion]], [[cardiac tamponade]], and pericardial constriction are rare <br> | |||
❑ Other clinical suspicion: <br> | |||
:❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease | |||
:❑ Early corticosteroid treatment causing augmented viral DNA/RNA replication </div>}} | |||
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Medications'''<br> | |||
❑ [[NSAIDs]] or [[aspirin]] <br> | |||
:❑ Same regimen as in acute pericarditis management | |||
❑ [[Colchicine]] <br> | |||
:❑ Same regimen as in acute pericarditis management | |||
:❑ Effective in cases where NSAIDs failed to prevent relapses | |||
❑ Exercise restriction <br> | |||
</div>}} | |||
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=Multiple relapses}} | |||
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Add [[corticosteroids]]'''<br> | |||
❑ [[Prednisone]]: 1-1.5 mg/kg x 1 month | |||
</div>}} | |||
{{familytree | | | | | | | | |,|-|^|-|.| | | | | | | | |}} | |||
{{familytree | | | | | | | | E01 | | E02 | | | | | | | | E01=Positive response| E02=No response}} | |||
{{familytree | | | | | | | | |!| | | |!| | | | | | | | |}} | |||
{{familytree | | | | | | | | F01 | | F02 | | | | | | | | F01=<div style="float: left; text-align: left; padding:1em;">'''Taper [[steroids]]'''<br> | |||
❑ Taper dose over a three-month period <br> | |||
:❑ If symptoms recur | |||
::❑ Start the last dose that suppressed the symptoms | |||
::❑ Maintain the dose for 2-3 weeks and then taper | |||
:❑ Add [[colchicine]] or [[NSAIDs]] at the end of tapering of steroids | |||
</div>| F02=<div style="float: left; text-align: left; padding:1em;"> | |||
❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br> | |||
</div>}} | |||
{{familytree | | | | | | | | |`|-|v|-|'| | | }} | |||
{{familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=Treatment failure}} | |||
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br> | |||
❑ Maintain the patient should on [[steroid]] free regimen for several weeks | |||
❑'''[[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Clinical testing for specific etiologies]]'''<br></div>}} | |||
{{familytree | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Line 282: | Line 372: | ||
! Clinical subgroups!! Specific investigations!! Treatment | ! Clinical subgroups!! Specific investigations!! Treatment | ||
|- | |- | ||
| Viral pericarditis|| ❑ Diagnostic [[pericardiocentesis]] <br> :❑ PCR or in-situ hybridisation || ❑ [[CMV]] pericarditis <br> :❑ Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16.<br>❑ [[Coxsackie B]] pericarditis<br> :❑ Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week<br> ❑ [[Adenovirus]] and [[parvovirus B19]] perimyocarditis <br> :❑ Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours | | Viral pericarditis|| ❑ Immunocompromised and HIV infected patients <br> ❑ Diagnostic [[pericardiocentesis]]<br> :❑ Analysis of pericardial fluid (transudate or exudate) <br> :❑ [[PCR]] or in-situ hybridisation || ❑ [[CMV]] pericarditis <br> :❑ Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16.<br>❑ [[Coxsackie B]] pericarditis<br> :❑ Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week<br> ❑ [[Adenovirus]] and [[parvovirus B19]] perimyocarditis <br> :❑ Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours | ||
|- | |- | ||
| | | Purulent pericarditis|| ❑ Diagnostic [[pericardiocentesis]] in cases of high clinical suspicion <br> :❑ [[Gram stain]], acid fast stain, fungal stain, and cultures of the pericardial fluid <br> :❑ Protein, glucose and cell count <br> ❑ Gram stain, acid fast stain, fungal stain, and cultures of other body fluids ||❑ Therapeutic [[pericardiocentesis]] or [[pericardial window]]<br> ❑ [[Pericardiectomy]] may be used in treatment of recurrent pericardial efussion and in patients with dense adhesions, loculated and thick purulent effusion<br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antimicrobial therapy]] <br> :❑ Intiate antistaphylococcal antibiotic plus [[aminoglycoside]], followed by tailored antibiotic therapy according to pericardial fluid and blood cultures<br> :❑ Empiric regimen can be started for the following <br> ::❑ [[Immunosuppression]]<br> ::❑ Concurrent infection at another body site<br> ::❑ Presence of intravascular lines or prosthetic devices <br> ::❑ Recent antimicrobial therapy <br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antifungal therapy]] | ||
|- | |- | ||
| [[Tuberculous pericarditis]]|| | | [[Tuberculous pericarditis]]|| ❑ Diagnostic [[pericardiocentesis]] in all suspected tuberculous pericarditis patients <br> :❑ [[PCR]] of pericardial fluid<br>:❑ High [[adenosine deaminase]] activity and interferon gamma concentration in [[pericardial effusion]] <br> ❑ Pericardial biopsy (rapid diagnosis) <br> ❑ [[Tuberculin skin test]] (not helpful) <br> ❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Culture of sputum, gastric aspirate, and/or urine <br>❑ Enzyme-linked immunospot (ELISPOT)<br> ❑ Serum titres of antimyolemmal and antimyosin antibodies||❑[[Tuberculous pericarditis medical therapy|Anti-tuberculosis chemotherapy]]<br> :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion<br> ❑ [[Pericardiectomy]] is warranted in the setting of persistent [[constrictive pericarditis]] or when no general improvement after 4-8 weeks following antituberculosis chemotherapy<br> ❑ [[Tuberculous pericarditis medical therapy#Role of Corticosteroids in Tuberculous pericarditis|Prednisone]] can be used. | ||
|- | |- | ||
| Neoplastic pericarditis ||❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Diagnostic [[pericardiocentesis]] <br> ❑ Pericardial biopsy || ❑ Systemic antineoplastic treatment <br> ❑ Assess the life expectancy of the patients before proceeding with the treatment<br> :❑ Better prognosis patients should be treated more aggressively <br> :❑ Advanced [[malignancy]] should be treated palliatively with [[pericardiocentesis]] <br> :❑ Recurrence of pericardial effusion is prevented using any of the following techniques <br> ::❑ Prolonged pericardiocentesis <br> ::❑ Pericardial sclerosis <br> ::❑ Pericardiotomy <br> ::❑ Intrapericardial chemotherapy | | Neoplastic pericarditis ||❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Diagnostic [[pericardiocentesis]] ❑ Cytology and tumour markers <br> ❑ Pericardial biopsy || ❑ Systemic antineoplastic treatment <br> ❑ Assess the life expectancy of the patients before proceeding with the treatment<br> :❑ Better prognosis patients should be treated more aggressively <br> :❑ Advanced [[malignancy]] should be treated palliatively with [[pericardiocentesis]] <br> :❑ Recurrence of pericardial effusion is prevented using any of the following techniques <br> ::❑ Prolonged pericardiocentesis <br> ::❑ Pericardial sclerosis <br> ::❑ Pericardiotomy <br> ::❑ Intrapericardial chemotherapy | ||
|- | |- | ||
| Pericarditis in renal failure ||❑ Renal function test <br> ❑ Diagnostic [[pericardiocentesis]] <br> ❑ Pericardial biopsy || ❑ Uremic pericarditis <br> :❑ [[Hemodialysis]] or [[peritoneal dialysis]]<br> :❑ [[Heparin]]-free haemodialysis should be used <br> ❑ Dialysis-associated pericarditis <br> :❑ [[Pericardiocentesis]] for large effusion <br> :❑ Pericardiotomy in non resolving effusion<br> | | Pericarditis in renal failure ||❑ Renal function test <br> ❑ Diagnostic [[pericardiocentesis]] <br> ❑ Pericardial biopsy || ❑ Uremic pericarditis <br> :❑ [[Hemodialysis]] or [[peritoneal dialysis]]<br> :❑ [[Heparin]]-free haemodialysis should be used <br> ❑ Dialysis-associated pericarditis <br> :❑ [[Pericardiocentesis]] for large effusion <br> :❑ Pericardiotomy in non resolving effusion<br> | ||
|- | |||
| Pericarditis in systemic autoimmune disease || ❑ Diagnostic [[pericardiocentesis]] <br> :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3<br> :❑ Antisarcolemmal antibodies<br> ❑ Exclusion of viral and bacterial etiologies|| ❑ [[NSAIDs]] or [[aspirin]] or [[colchicine]] <br> ❑ Systemic [[corticosteroid]] can be used <br> :❑ Intrapericardial steroids has less side effects and is highly effective | |||
|- | |- | ||
|} | |} | ||
==Do's== | ==Do's== | ||
* | |||
* | |||
* | |||
* | |||
* [[NSAIDs]] are the mainstay in the treatment of uncomplicated [[acute pericarditis]] and [[ibuprofen]] is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range. | |||
* Systemic [[corticosteroid]] therapy should be restricted to autoimmune or [[uremic pericarditis]] and [[ibuprofen]] or [[colchicine]] should be introduced early during tapering of steroids. | |||
* [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy. | |||
* Systemic corticosteroid therapy should be restricted to connective tissue diseases, autoreactive or uremic pericarditis. Intrapericardial application avoids systemic side effects and is highly effective. | |||
* Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation. | |||
* Monitor closely patients who underwent pericardiocentesis for postdrainage decompensation. | |||
==Dont's== | ==Dont's== | ||
* | |||
* | |||
* | |||
* | |||
* Avoid pericardiocentesis in cases where the diagnosis can be made based on other systemic features or when the effusions are very small or resolving under antiinflammatory treatment | |||
* Don't perform pericardiocentesis in [[aortic dissection]] and ruptured [[ventricular aneurysm]] and avoid in cases of uncorrected coagulopathy, anticoagulant therapy, [[thrombocytopenia]] < 50,000/mm 3 , small, posterior, and loculated effusions. | |||
==References== | ==References== |
Revision as of 19:56, 14 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]
Overview
Acute pericarditis refers to inflammation of the pericardial sac, which can be dry, fibrinous or effusive, independent from its aetiology. The term myopericarditis, or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation resulting in global or regional myocardial dysfunction, elevations of troponins, MB creatine kinase, myoglobin and tumour necrosis factor.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Autoimmune: Rheumatoid arthritis, Sjögren’s syndrome, SLE, systemic sclerosis, systemic vasculitis
- Bacterial: Coxiella burnetii, pneumococcus, staphylococcus, streptococcus, tuberculosis
- Cardiovascular: Dressler's syndrome, postpericardiotomy syndrome, posttraumatic pericarditis
- Idiopathic
- Metabolic: Myxedema, uremia
- Neoplastic: Breast cancer, leukemia, lung cancer, lymphoma
- Viral: Adeno virus, CMV, coxsackie, EBV, echovirus, HBV, HIV, human herpes virus 6, influenza, mumps, parvovirus B19, rubella, varicella
Management
The following is an algorithm depicting the management of acute pericarditis in adults.[1][2][3]
Characterize the clinical, EKG and imaging findings ❑ Characteristic chest pain
❑ Suggestive EKG changes
❑ Suggestive echocardiography changes
| |||||||||||||||||||||||||||||||||||||||||||||||||
Consider a possible diagnosis of acute pericarditis | |||||||||||||||||||||||||||||||||||||||||||||||||
Characterize the symptoms: Symptoms suggestive of pericarditis:
Symptoms associated with pericardial effusion:
❑ With a hemodynamically significant pericardial effusion
Other associated symptoms: Obtain a detailed history:
❑ Medications
❑ Systemic illness ❑ Others
| |||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Vitals
❑ Cardiovascular:
❑ Respiratory system:
❑ Abdominal examination
| |||||||||||||||||||||||||||||||||||||||||||||||||
Order laboratory tests (urgent): ❑ CBC: Leucocytosis Order electrocardiogram (urgent): ❑ Typical findings in pericarditis
❑ Electrical alternans (in cardiac tamponade) Order imaging (urgent):
| |||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of acute pericarditis: Atleast two of the following criteria: | |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No or equivocal | ||||||||||||||||||||||||||||||||||||||||||||||||
Acute pericarditis Or ❑ Elevated cardiac enzymes | Consider cardiac MRI (CMR) | Consider alternative diagnosis and treat accordingly | |||||||||||||||||||||||||||||||||||||||||||||||
Treat as acute pericarditis or myopericarditis if there is delayed enhancement on CMR | |||||||||||||||||||||||||||||||||||||||||||||||||
High risk features ❑ Fever >38°C | |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||
Inpatient treatment | Outpatient treatment | ||||||||||||||||||||||||||||||||||||||||||||||||
Stable | No pre-existing coronary artery disease | Pre-existing coronary artery disease | |||||||||||||||||||||||||||||||||||||||||||||||
❑ NSAID's or aspirin or colchicine (usual regimen)
❑ Management of recurrent pericarditis
| ❑ Immediately transfer the patient to ICU
❑ Make sure patient is oxygenating well
| NSAID's ❑ Ibuprofen:
❑ Indomethacin:
❑ Add gastroprotective agents
❑ Alone or in combination with NSAIDs ❑ Avoid steroids to treat an initial episode of pericarditis | Aspirin
❑ Add gastroprotective agents
❑ Stop anticoagulants if patient develops pericardial effusion ❑ Avoid steroids to treat an initial episode of pericarditis | ||||||||||||||||||||||||||||||||||||||||||||||
Response to Rx | |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||
Follow up ❑ Observe for recurrences or constriction | Hospital admission ❑ Indication that the underlying cause may not be viral or idiopathic in nature. | ||||||||||||||||||||||||||||||||||||||||||||||||
Management of Recurrent Pericarditis
Recurrent pericarditis | |||||||||||||||||||||||||||||||||||||||||||||||||
The intermittent type ❑ Symptom free interval without therapy | The incessant type ❑ Always relapses on discontinuation of anti-inflammatory | ||||||||||||||||||||||||||||||||||||||||||||||||
Characterize the clinical, EKG and imaging findings ❑ Characteristic acute pericarditis symptoms
| |||||||||||||||||||||||||||||||||||||||||||||||||
Medications
❑ Exercise restriction | |||||||||||||||||||||||||||||||||||||||||||||||||
Multiple relapses | |||||||||||||||||||||||||||||||||||||||||||||||||
Positive response | No response | ||||||||||||||||||||||||||||||||||||||||||||||||
Taper steroids ❑ Taper dose over a three-month period
| ❑ Add azathioprine (75–100 mg/day) or cyclophosphamide | ||||||||||||||||||||||||||||||||||||||||||||||||
Treatment failure | |||||||||||||||||||||||||||||||||||||||||||||||||
Pericardiectomy ❑ Maintain the patient should on steroid free regimen for several weeks ❑Clinical testing for specific etiologies | |||||||||||||||||||||||||||||||||||||||||||||||||
Etiology Specific Management
Clinical subgroups | Specific investigations | Treatment |
---|---|---|
Viral pericarditis | ❑ Immunocompromised and HIV infected patients ❑ Diagnostic pericardiocentesis :❑ Analysis of pericardial fluid (transudate or exudate) :❑ PCR or in-situ hybridisation |
❑ CMV pericarditis :❑ Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16. ❑ Coxsackie B pericarditis :❑ Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week ❑ Adenovirus and parvovirus B19 perimyocarditis :❑ Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours |
Purulent pericarditis | ❑ Diagnostic pericardiocentesis in cases of high clinical suspicion :❑ Gram stain, acid fast stain, fungal stain, and cultures of the pericardial fluid :❑ Protein, glucose and cell count ❑ Gram stain, acid fast stain, fungal stain, and cultures of other body fluids |
❑ Therapeutic pericardiocentesis or pericardial window ❑ Pericardiectomy may be used in treatment of recurrent pericardial efussion and in patients with dense adhesions, loculated and thick purulent effusion ❑ Antimicrobial therapy :❑ Intiate antistaphylococcal antibiotic plus aminoglycoside, followed by tailored antibiotic therapy according to pericardial fluid and blood cultures :❑ Empiric regimen can be started for the following ::❑ Immunosuppression ::❑ Concurrent infection at another body site ::❑ Presence of intravascular lines or prosthetic devices ::❑ Recent antimicrobial therapy ❑ Antifungal therapy |
Tuberculous pericarditis | ❑ Diagnostic pericardiocentesis in all suspected tuberculous pericarditis patients :❑ PCR of pericardial fluid :❑ High adenosine deaminase activity and interferon gamma concentration in pericardial effusion ❑ Pericardial biopsy (rapid diagnosis) ❑ Tuberculin skin test (not helpful) ❑ CT scan and/or MRI of the chest ❑ Culture of sputum, gastric aspirate, and/or urine ❑ Enzyme-linked immunospot (ELISPOT) ❑ Serum titres of antimyolemmal and antimyosin antibodies |
❑Anti-tuberculosis chemotherapy :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion ❑ Pericardiectomy is warranted in the setting of persistent constrictive pericarditis or when no general improvement after 4-8 weeks following antituberculosis chemotherapy ❑ Prednisone can be used. |
Neoplastic pericarditis | ❑ CT scan and/or MRI of the chest ❑ Diagnostic pericardiocentesis ❑ Cytology and tumour markers ❑ Pericardial biopsy |
❑ Systemic antineoplastic treatment ❑ Assess the life expectancy of the patients before proceeding with the treatment :❑ Better prognosis patients should be treated more aggressively :❑ Advanced malignancy should be treated palliatively with pericardiocentesis :❑ Recurrence of pericardial effusion is prevented using any of the following techniques ::❑ Prolonged pericardiocentesis ::❑ Pericardial sclerosis ::❑ Pericardiotomy ::❑ Intrapericardial chemotherapy |
Pericarditis in renal failure | ❑ Renal function test ❑ Diagnostic pericardiocentesis ❑ Pericardial biopsy |
❑ Uremic pericarditis :❑ Hemodialysis or peritoneal dialysis :❑ Heparin-free haemodialysis should be used ❑ Dialysis-associated pericarditis :❑ Pericardiocentesis for large effusion :❑ Pericardiotomy in non resolving effusion |
Pericarditis in systemic autoimmune disease | ❑ Diagnostic pericardiocentesis :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3 :❑ Antisarcolemmal antibodies ❑ Exclusion of viral and bacterial etiologies |
❑ NSAIDs or aspirin or colchicine ❑ Systemic corticosteroid can be used :❑ Intrapericardial steroids has less side effects and is highly effective |
Do's
- NSAIDs are the mainstay in the treatment of uncomplicated acute pericarditis and ibuprofen is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range.
- Systemic corticosteroid therapy should be restricted to autoimmune or uremic pericarditis and ibuprofen or colchicine should be introduced early during tapering of steroids.
- Heparin is recommended under strict observation for patients who need anticoagulant therapy.
- Systemic corticosteroid therapy should be restricted to connective tissue diseases, autoreactive or uremic pericarditis. Intrapericardial application avoids systemic side effects and is highly effective.
- Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation.
- Monitor closely patients who underwent pericardiocentesis for postdrainage decompensation.
Dont's
- Avoid pericardiocentesis in cases where the diagnosis can be made based on other systemic features or when the effusions are very small or resolving under antiinflammatory treatment
- Don't perform pericardiocentesis in aortic dissection and ruptured ventricular aneurysm and avoid in cases of uncorrected coagulopathy, anticoagulant therapy, thrombocytopenia < 50,000/mm 3 , small, posterior, and loculated effusions.
References
- ↑ Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y; et al. (2004). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". Eur Heart J. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. PMID 15120056.
- ↑ Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B; et al. (2013). "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography". J Am Soc Echocardiogr. 26 (9): 965–1012.e15. doi:10.1016/j.echo.2013.06.023. PMID 23998693.
- ↑ Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010). "Controversial issues in the management of pericardial diseases". Circulation. 121 (7): 916–28. doi:10.1161/CIRCULATIONAHA.108.844753. PMID 20177006.